430 related articles for article (PubMed ID: 29133589)
1. Precision Oncology beyond Targeted Therapy: Combining Omics Data with Machine Learning Matches the Majority of Cancer Cells to Effective Therapeutics.
Ding MQ; Chen L; Cooper GF; Young JD; Lu X
Mol Cancer Res; 2018 Feb; 16(2):269-278. PubMed ID: 29133589
[TBL] [Abstract][Full Text] [Related]
2. Beyond the limitation of targeted therapy: Improve the application of targeted drugs combining genomic data with machine learning.
Miao R; Chen HH; Dang Q; Xia LY; Yang ZY; He MF; Hao ZF; Liang Y
Pharmacol Res; 2020 Sep; 159():104932. PubMed ID: 32473309
[TBL] [Abstract][Full Text] [Related]
3. Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine.
Zhu Z; Ihle NT; Rejto PA; Zarrinkar PP
BMC Genomics; 2016 Jun; 17():455. PubMed ID: 27296290
[TBL] [Abstract][Full Text] [Related]
4. Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S; Sun SQ; Huang KL; Oh C; Bailey MH; Varghese R; Wyczalkowski MA; Ning J; Tripathi P; McMichael JF; Johnson KJ; Kandoth C; Welch J; Ma C; Wendl MC; Payne SH; Fenyö D; Townsend RR; Dipersio JF; Chen F; Ding L
Genome Med; 2018 Jul; 10(1):60. PubMed ID: 30053901
[TBL] [Abstract][Full Text] [Related]
5. DeepDRK: a deep learning framework for drug repurposing through kernel-based multi-omics integration.
Wang Y; Yang Y; Chen S; Wang J
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33822890
[TBL] [Abstract][Full Text] [Related]
6. PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data.
Piñeiro-Yáñez E; Reboiro-Jato M; Gómez-López G; Perales-Patón J; Troulé K; Rodríguez JM; Tejero H; Shimamura T; López-Casas PP; Carretero J; Valencia A; Hidalgo M; Glez-Peña D; Al-Shahrour F
Genome Med; 2018 May; 10(1):41. PubMed ID: 29848362
[TBL] [Abstract][Full Text] [Related]
7. Network-Based Matching of Patients and Targeted Therapies for Precision Oncology.
Liu Q; Ha MJ; Bhattacharyya R; Garmire L; Baladandayuthapani V
Pac Symp Biocomput; 2020; 25():623-634. PubMed ID: 31797633
[TBL] [Abstract][Full Text] [Related]
8. Optimal drug prediction from personal genomics profiles.
Sheng J; Li F; Wong ST
IEEE J Biomed Health Inform; 2015 Jul; 19(4):1264-70. PubMed ID: 25781964
[TBL] [Abstract][Full Text] [Related]
9. RefDNN: a reference drug based neural network for more accurate prediction of anticancer drug resistance.
Choi J; Park S; Ahn J
Sci Rep; 2020 Feb; 10(1):1861. PubMed ID: 32024872
[TBL] [Abstract][Full Text] [Related]
10. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
Albin N; Mc Leer A; Sakhri L
Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
[TBL] [Abstract][Full Text] [Related]
11. GMIEC: a shiny application for the identification of gene-targeted drugs for precision medicine.
Malagoli Tagliazucchi G; Taccioli C
BMC Genomics; 2020 Sep; 21(1):619. PubMed ID: 32912170
[TBL] [Abstract][Full Text] [Related]
12. Cancer Precision Medicine: Why More Is More and DNA Is Not Enough.
Schütte M; Ogilvie LA; Rieke DT; Lange BMH; Yaspo ML; Lehrach H
Public Health Genomics; 2017; 20(2):70-80. PubMed ID: 28595192
[TBL] [Abstract][Full Text] [Related]
13. Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery.
Bryce AH; Egan JB; Borad MJ; Stewart AK; Nowakowski GS; Chanan-Khan A; Patnaik MM; Ansell SM; Banck MS; Robinson SI; Mansfield AS; Klee EW; Oliver GR; McCormick JB; Huneke NE; Tagtow CM; Jenkins RB; Rumilla KM; Kerr SE; Kocher JA; Beck SA; Fernandez-Zapico ME; Farrugia G; Lazaridis KN; McWilliams RR
Oncotarget; 2017 Apr; 8(16):27145-27154. PubMed ID: 28423702
[TBL] [Abstract][Full Text] [Related]
14. Evidence-Based Precision Oncology with the Cancer Targetome.
Blucher AS; Choonoo G; Kulesz-Martin M; Wu G; McWeeney SK
Trends Pharmacol Sci; 2017 Dec; 38(12):1085-1099. PubMed ID: 28964549
[TBL] [Abstract][Full Text] [Related]
15. Drug Response Prediction by Globally Capturing Drug and Cell Line Information in a Heterogeneous Network.
Le DH; Pham VH
J Mol Biol; 2018 Sep; 430(18 Pt A):2993-3004. PubMed ID: 29966608
[TBL] [Abstract][Full Text] [Related]
16. PLATYPUS: A Multiple-View Learning Predictive Framework for Cancer Drug Sensitivity Prediction.
Graim K; Friedl V; Houlahan KE; Stuart JM
Pac Symp Biocomput; 2019; 24():136-147. PubMed ID: 30864317
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy in cancer.
Tsimberidou AM
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1113-32. PubMed ID: 26391154
[TBL] [Abstract][Full Text] [Related]
18. Cancer Drug Response Profile scan (CDRscan): A Deep Learning Model That Predicts Drug Effectiveness from Cancer Genomic Signature.
Chang Y; Park H; Yang HJ; Lee S; Lee KY; Kim TS; Jung J; Shin JM
Sci Rep; 2018 Jun; 8(1):8857. PubMed ID: 29891981
[TBL] [Abstract][Full Text] [Related]
19. Bioinformatics Approaches to Predict Drug Responses from Genomic Sequencing.
Madhukar NS; Elemento O
Methods Mol Biol; 2018; 1711():277-296. PubMed ID: 29344895
[TBL] [Abstract][Full Text] [Related]
20. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
Daher A; de Groot J
Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
